Sentences with phrase «receptor tyrosine kinase»

Investigated TAM family receptor tyrosine kinase gene expression in response to small molecule inhibitors in glioblastoma multiforme

Multi-center, placebo - controlled, double - blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.

[1] DIM was found to have «lung cancer preventive effects» mediated via modulation of the receptor tyrosine kinase / PI3K / Akt - signaling pathway.

In addition to causing the functional inactivation of these phosphatases, low concentrations of H2O2 or an oxidative shift in the GSH: GSSH redox status strongly increases the activity of the basic insulin receptor tyrosine kinase in the absence of insulin.

In addition, at least some Eph receptors can also signal through non-canonical mechanisms that are independent of ligand binding and kinase activity, for example through interplay with other receptor tyrosine kinase families and with serine / threonine kinases.

These mutant kinases are attractive therapeutic targets, as demonstrated by the efficacy of imatinib in BCR - ABL — positive chronic myelogenous leukemia (CML), 5 as well as in MPD associated with activating alleles involving PDGFRA or PDGFRB.2, 6,7 In addition, activating mutations in the FLT3 receptor tyrosine kinase are the most common genetic event in acute myeloid leukemia (AML), and specific inhibitors of the FMS - like tyrosine kinase 3 (FLT3) have entered late - stage clinical trials.8 Although mutations in tyrosine kinases and in other genes have been identified in a subset of MPD and AML, in many cases the genetic events that contribute to the molecular pathogenesis of these diseases remain unknown.

Further, we identified a role for ABL kinases in promoting the expression of multiple pro — bone metastasis genes such as AXL (which encodes a receptor tyrosine kinase), IL6 (which encodes interleukin - 6), MMP1 (which encodes matrix metalloproteinase 1), and TNC (which encodes tenascin - C) through TAZ - and signal transducer and activator of transcription 5 (STAT5)-- mediated signaling.

AXL encodes a receptor tyrosine kinase that promotes breast cancer bone metastasis in mouse models (41).

[42 - 46] KIT, a type III transmembrane receptor tyrosine kinase that sits upstream of NRAS and BRAF, feeds into several signaling pathways, including both the RAS / RAF / MEK / ERK cascade and the PI3K / Akt / mTOR pathway.

Expression of the receptor tyrosine kinase Tie2 in neoplastic glial cells is associated with integrin beta1 - dependent adhesion to the extracellular matrix.

Sina Koch (Ehninger, TUD)-- «Aberrant subcellular localization as a potential mechanism contributing to the abnormal signaling of the mutant Flt3 - ITd receptor tyrosine kinase in acute myeloid leukemia» (2007)

Human phospho - receptor tyrosine kinase array was performed according to the manufacturer's instructions (R&D, #ARY001B).

Quantity Control of the ErbB3 Receptor Tyrosine Kinase at the Endoplasmic Reticulum.

Mouse angiogenesis and phospho - receptor tyrosine kinase array were performed according to the manufacturer's instructions (R&D, #ARY015 and #ARY014).

(h) Human phospho - receptor tyrosine kinase array for EphA2, EphB2 and EphB4 ephrin receptors from control BP (shCtr) and BP silenced for Tie2 (siTie2 I and siTie2 II).

We are focusing on a few key molecular pathways including; 1) Polycomb - mediated epigenetic gene silencing in the tumor initiation, maintenance, and invasion, 2) c - Met (receptor tyrosine kinase) signal transduction pathways in stemness and migration of these tumor cells, 3) Novel mitogenic signaling pathways that are specific to GSCs, and 4) Identification of radio - and chemo - sensitizing pathway to maximize therapeutic efficacy.

In 2005, Cagan's team created a general fly model of a human thyroid tumor caused by mutations in the Ret receptor tyrosine kinase gene, then screened a panel of drugs including a kinase inhibitor called vandetanib that suppressed the tumor (Cancer Res, 65:3538 - 41, 2005).

RET is a type of receptor tyrosine kinase, and mutations that kick its activity into overdrive are linked to certain kinds of cancer.

They found higher levels of JAK1 in resistant tumors, which caused increased expression of epidermal growth factor receptor (EGFR)-- a receptor tyrosine kinase that promotes cell proliferation.

Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement in survival without progression of the cancer, but not with overall survival, according to a study in the April 9 issue of JAMA.

When PDGF arrives at the cell surface, it binds to a protein called PDGF receptor tyrosine kinase (PDGF RTK).

These receptors, called receptor tyrosine kinases (RTKs), transmit instructions through the cell wall and down through a cascade of reactions to a target gene in the nucleus.

And, indeed, previous research has shown that receptor tyrosine kinases, e.g. insulin receptors, and cytokine receptors, e.g. growth hormone receptors, exist in dimeric form even in the absence of ligands.

During the early years of my PhD studies, I was very fascinated by the exciting discoveries in the field of signal transduction, in particular how receptor tyrosine kinases are activated to transmit their signals and how protein complexes are formed through defined protein folds (domains) interacting with specific cellular targets.

In 1995, I began graduate studies on signal transduction by growth factors and receptor tyrosine kinases in the laboratory of Graeme Guy at the Institute of Molecular and Cell Biology (IMCB) in Singapore, obtaining my PhD in 2000.

Ari Hashimoto and colleagues found that the MVP promotes the recruitment of Arf6 to the plasma membrane, where it can be activated by receptor tyrosine kinases.

We review progress with the receptor tyrosine kinases (growth factor receptors EGFR, VEGFR, and FGFR) and nonreceptor tyrosine kinases (Bcr - Abl), where advances have been made with cancer therapeutic agents such as Herceptin and Gleevec.

These events occur when specific extracellular molecules bind to receptor proteins in the plasma membrane known as receptor tyrosine kinases and heterotrimeric G - protein - coupled receptors.

Receptor Tyrosine Kinases and TLR / IL1Rs Unexpectedly Activate Myeloid Cell PI3K [gamma], A Single Convergent Point Promoting Tumor Inflammation and Progression.

The researchers also screened more than 100 anticancer compounds to see whether they killed lab - grown cancer cells from the devils and found that both strains responded to inhibitors of proteins known as receptor tyrosine kinases.

Also, genes that code for receptor tyrosine kinases, a family of receptors on the surface of cells, may rearrange to form multiple distinct gene fusion partners, as evidenced in an article by Kulkarni, et al, on a translational study involving a patient who developed a BRAF fusion following treatment with a BRAF inhibitor1.

Receptor tyrosine kinases of the Eph family and their ligands, the ephrins, represent an important cell communication system that controls a vast array physiological and disease processes.

They found that certain GBM tumors — particularly those deficient in PTEN — had multiple co-activated receptor tyrosine kinases (RTKs).

Not exact matches

The Janus tyrosine kinases (Jaks) play a central role in signaling through cytokine receptors.

The target for ibrutinib, an enzyme called Bruton's tyrosine kinase (BTK), is a key component of B - cell receptor signaling.

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for patients with advanced non-small cell lung cancer (NSCLC) who have mutations in the EGFR gene.

PDGFRα is a cell surface tyrosine kinase receptor involved in organ development and tumor progression, it is present in multiple cell types such as mesenchymal cells, neurons, astrocytes, megakaryocytes and oligodendrocyte progenitor.

Approximately 10 - 15 % of Caucasian and 30 - 35 % of Asian patients with NSCLC have a mutation in the epidermal growth factor receptor (EGFR), which can be successfully targeted with EGFR inhibitors called tyrosine kinase inhibitors (TKI), such as erlotinib, gefitinib and afatinib.

The researchers, including scientists from pharmaceutical company AstraZeneca, report in an advanced online publication in Nature Medicine on May 4, that their findings indicate «an underappreciated genomic heterogeneity» in mechanisms of resistance to tyrosine kinase inhibitor (TKI) drugs that target the Epidermal Growth Factor Receptor (EGFR) mutation that drive some cases of non-small cell lung cancer (NSCLC).

Gene expression in papillary thyroid carcinomas, with special reference to tyrosine kinase receptors and growth factors.

Using immunohistochemistry, we detected basal levels of the tyrosine kinase receptors Flk - 1, FGFR - 1, and Tie - 2.

We also noted constitutive surface expression of the tyrosine kinase receptors Tie - 2, FGFR - 1, and Flk - 1 on proliferating and resting endothelial cells (data not shown).

D'Oro, U., Vacchio, M.S., Weissman, A.M. & Ashwell, J.D. Activation of the Lck tyrosine kinase targets cell surface T cell antigen receptors for lysosomal degradation.

Aminoglycoside - induced degeneration of adult spiral ganglion neurons involves differential modulation of tyrosine kinase B and p75 neurotrophin receptor signaling.

Signal transduction through the T - lymphocyte CD4 receptor involves the activation of the internal membrane tyrosine - protein kinase p56lck.

Scanning electron micrograph of the coronary microvasculature of a mouse that has been treated with a small molecule tyrosine kinase inhibitor of platelet - derived growth factor receptor beta.

The initial model for STAT signaling involves a specific cytokine binding to its cognate receptor and promoting the transphosphorylation of receptor associated tyrosine kinases from the Janus - activated kinase family (JAK).

Muller, W. E. & Schacke, H. Characterization of the receptor protein - tyrosine kinase gene from the marine sponge Geodia cydonium.

Binding to ephrin ligands on the surface of neighboring cells induces canonical signaling involving receptor clustering, autophosphorylation on tyrosine residues, and kinase activity - dependent downstream signaling.

We also found that the SRC and ABL non-receptor tyrosine kinases and the SHEP1 scaffolding protein are binding partners of the Eph receptors, and we identified signaling connections between Eph receptors and integrins.